Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Trading Update

30 Sep 2014 07:00

RNS Number : 9598S
Royal Bank of Scotland Group PLC
30 September 2014
 



The Royal Bank of Scotland Group plc ("RBS")

 

Q3 2014 Trading Update and Presentation at Bank of America Merrill Lynch Banking & Insurance Conference

 

30 September 2014

 

Presentation at Bank of America Merrill Lynch Banking & Insurance Conference

 

Ross McEwan, RBS Chief Executive, will present at the Bank of America Merrill Lynch Banking & Insurance Conference in London on Tuesday 30 September 2014 at 9.30am (UK time). 

 

A live audio webcast and accompanying slides will be available on our website www.rbs.com/ir shortly before the presentation commences.

 

Q3 2014 Trading Update

 

RBS today provides an update on Q3 2014 financial performance.

 

· Q3 2014 has seen continued improvement in economic conditions and asset prices in our key markets, including Ireland. This has supported a further quarter of strong operating performance by RBS Capital Resolution ("RCR"). We anticipate that RCR will record net impairment provision releases in the region of £0.5bn in Q3 2014.

 

· RCR's future overall costs and speed of wind-down remain subject to significant potential volatility. The potential exists, if market conditions remain favourable, for RCR to incur limited future impairments and disposal losses, and an accelerated timetable to achieve its wind-down goals.

 

· Rising Irish residential property prices combined with pro-active debt management has resulted in lower arrears in Ulster (excluding RCR), within Personal & Business Banking. As a result we expect Ulster to record net provision releases in the region of £0.3bn in Q3 2014. The potential exists for further releases in future, if market conditions continue to improve.

 

· There has been an absence of large one-off impairments and lower levels of new non-performing loans in the rest of RBS's business during Q3 2014.

 

· RBS now expects to significantly outperform its previous guidance of c£1bn total impairments for FY 2014. Previously disclosed uncertainties remain, particularly relating to conduct and litigation matters.

 

· Corporate & Institutional Banking revenues have been weaker than anticipated in the third quarter.

 

· RBS took advantage of improved market prices to dispose of c€9bn legacy available for sale debt securities. These disposals generated a loss of around £0.2bn in Centre revenues. We expect these transactions to be moderately capital ratio accretive.

 

The figures quoted in this statement are preliminary estimates and unaudited. RBS will release its Q3 2014 Interim Management Statement on 31 October 2014.

 

 

For further information:

 

Investor Relations

Richard O'Connor

Head of Investor Relations

+44 (0) 20 7672 1758

 

Media Relations

+44 (0) 131 523 4205

 

If you would like a copy of this presentation in a different format (eg. large print, audio or Braille) please contact the Investor Relations team on +44 20 7672 1758 or investor.relations@rbs.com.

 

This release contains 'forward-looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995. Forward looking statements are statements that are not historical facts and can be identified by the use of forward-looking terminology such as statements that include the words 'expect', 'estimate', 'project', 'anticipate', 'believes', 'should', 'intend', 'plan', 'could', 'probability', 'risk', 'Value-at-Risk (VaR)', 'target', 'goal', 'objective', 'will', 'endeavour', 'outlook', 'optimistic', 'prospects' and similar expressions or variations on such expressions or by the forward looking nature of discussions of strategy, plans, targets and intentions. . These statements are based on current plans, estimates and projections, and are subject to inherent risks, uncertainties and other factors which could cause actual results to differ materially from the future results expressed or implied by such forward-looking statements. The forward-looking statements contained in this release speak only as of the date of this announcement, and the Group does not undertake to update any forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The information, statements and opinions contained in this document do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

 

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKKDPPBKKKCN
Date   Source Headline
5th Nov 20184:21 pmRNSPublication of Suppl.Prospcts
2nd Nov 20185:25 pmRNSPublication of 2018 EBA EU-wide stress test result
2nd Nov 20182:10 pmRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSUK intra-Group capital & liquidity arrangements
31st Oct 20182:38 pmRNSTotal Voting Rights
31st Oct 20187:00 amRNSDividend Declaration
30th Oct 20184:05 pmRNSDirector/PDMR Shareholding
29th Oct 20183:46 pmRNSDirector/PDMR Shareholding
26th Oct 20187:00 amRNSInterim Management Statement
9th Oct 20182:07 pmRNSForm 8.3 - CareTech Holdings
4th Oct 201812:43 pmRNSForm 8.3 - CareTech Holdings
4th Oct 201812:25 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Oct 20183:00 pmRNSDirector/PDMR Shareholding
28th Sep 201812:32 pmRNSTotal Voting Rights
25th Sep 201811:23 amRNSPricing of USD Fixed Rate to Floating Rate Notes
25th Sep 20187:00 amRNSBofAML Annual Financial CEO Conference
24th Sep 20189:00 amRNSRBS Investor SeminarUK Personal & Business Banking
17th Sep 201812:05 pmRNSPublication of Final Terms
13th Sep 201812:25 pmRNSForm 8.3 - CareTech Holdings
13th Sep 20188:00 amRNSBarclays Global Financial Services Conference
3rd Sep 20186:00 pmRNSPublication of Final Terms
31st Aug 20184:42 pmRNSTotal Voting Rights
31st Aug 20184:15 pmRNSNatWest Markets N.V. Interim Results 2018
22nd Aug 20185:01 pmRNSDividend Declaration
21st Aug 20183:32 pmRNSPublication of Suppl.Prospcts
17th Aug 20187:00 amRNSDirectorate Change
15th Aug 20187:00 amRNSDeclaration of Interim Dividend
13th Aug 20189:00 amRNSUpdate on ring-fencing plans
3rd Aug 20182:25 pmRNSForm 8.3 - [CareTech Holdings]
3rd Aug 20187:00 amRNSHalf-year Report
31st Jul 20182:44 pmRNSUpdate on ring-fencing plans
31st Jul 201812:04 pmRNSTotal Voting Rights
26th Jul 201812:17 pmRNSForm 8.3 - CareTech Holdings PLC
23rd Jul 20182:10 pmRNSForm 8.3 - CareTech Holdings plc
17th Jul 201811:46 amRNSRBS welcomes credit ratings action by Moody's
16th Jul 20186:18 pmRNSAllotment and Issue of New Ordinary Shares
16th Jul 20184:18 pmRNSForm 8.3 - CareTech Holdings plc
2nd Jul 20182:47 pmRNSCapital reduction - notice of completion
29th Jun 201812:51 pmRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 201811:52 amRNSPublication of Final Terms
22nd Jun 20185:28 pmRNSPublication of Final Terms
21st Jun 201811:52 amRNSPricing of USD Dual-Tranche Notes
8th Jun 20189:23 amRNSTR-1 Notification of major shareholdings
7th Jun 20189:00 amRNSGoldman Sachs European Financials Conference
5th Jun 20187:00 amRNSDisposal of approximately 7.7% of RBS Group plc.
4th Jun 20184:36 pmRNSIntention to dispose of c7.7% of RBS Group plc.
31st May 20185:32 pmRNSTotal Voting Rights
31st May 20184:30 pmRNSRBS notes credit rating actions by Standard&Poor's
31st May 201812:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.